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tasis. VGA often presents as at least stage IB1, however conservative
management has been described (Jones et al., 1993).
Therefore, it is important to differentiate this variant from other
cervical carcinomas because of the indolent nature of VGA and possibil-
ity for fertility-sparing or less morbid treatment. This is especially
salient given that this tumor can occur in young, reproductive age
women. In this paper, we describe two cases of villoglandular adenocar-
cinoma (VGA) at our institution, with evidence supporting conservative
management of early stage disease. Conservative management in thisVilloglandular adenocarcinoma of the cervix (VGA) is a rare subset
of cervical cancer. Unique features of this variant include its young age
of onset, exophytic presentation and superﬁcial involvement of the
underlying cervical tissue. It has been suggested that this variant has
an excellent prognosis and may be managed conservatively when
compared to more common squamous cell or adenocarcinoma vari-
ants (Lataifeh et al., 2013). A literature review of papers published
between 2000 and 2013 was performed using PubMed search terms
“villoglandular” “cervical” and “adenocarcinoma”. Given the paucity of
research in this area, additional peer-reviewed articles were found
through reviewing the bibliographies of identiﬁed references.
Villoglandular adenocarcinomawasﬁrst described in 1989 byYoung
and Scully, in their report of 13 patients with an average age of 33
(Young and Scully, 1989). A young age of incidence has been supported
with subsequent series, ranging from 36–45 by different authors
(Young and Scully, 1989; Jones et al., 1993; Korach et al., 2009;
Utsugi et al., 2004). The typical presentation is an exophytic lesion
that is ﬁrst detected after irregular vaginal bleeding, postcoital bleeding,
or abnormal Pap smear (Jones et al., 1993; Korach et al., 2009; Garcea
et al., 2003). This tumor is typically thought to be a slow-growinguw.edu (C. Newbill),
.org (E. Munro).
ent of Pathology, Box 357470,
n, MA 01805, United States.
. This is an open access article undersetting is deﬁned as less invasive surgical treatment without adjuvant
radiation therapy, including local excision with cold knife cone or
extrafascial hysterectomy, as opposed to radical hysterectomy with
or without radiation therapy.Case reports
Two patients were diagnosed with villoglandular adenocarcinoma
of the cervix at our institution during the last 5 years. Both were
women in their thirties who presented with postcoital vaginal bleeding
and were diagnosed with Stage IB1 villoglandular adenocarcinoma.
Both cases were managed conservatively, one with cold knife cone
excisional biopsy (CKC), and one with CKC followed by simple hys-
terectomy. At 41 and 18 months respectively, both patients showed
no evidence of disease.Case 1
A 37-year-old female presented to a general gynecologist with post-
coital bleeding and mucousy discharge. An exophytic lesion of the
cervix was biopsied. The review of pathology revealed villoglandular
adenocarcinoma of the cervix, and she was referred to a gynecologic
oncologist. The decision was made to proceed with a cervical cold
knife conization. Prior to her procedure, the patient underwentmagnet-
ic resonance imaging (MRI) of the pelvis showing focal cervical abnor-
mality at the external os without evidence of local extension. On CKC,
an approximately three centimeter exophytic cervical lesion protruding
from the endocervix was visualized. Pathology conﬁrmed well-
differentiated endocervical adenocarcinoma, villoglandular variant.
Focal minimal stromal invasion (1–2 mm) was present, with no signif-
icant nuclear atypia and no lymphovascular space invasion. Given thatthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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was carried out. Follow-up is being conducted according to SGO guide-
lines for cervical cancer (Salani et al., 2011), and she remains with no
evidence of disease at 41 months.
Case 2
A 33-year-old female presented to a general gynecologist after a
one-year history of postcoital bleeding. She had been previously evalu-
ated in an outside hospital emergency department andwas referred for
a “mass” seen on her cervix. Her most recent Pap smear was two years
prior and was negative. She did have a remote history of abnormal Pap
smear 12 years prior, the details of which were not available. On exam
therewas a 2–3 cmpolypoid exophyticmass protruding from the exter-
nal cervical os, which was assumed to be a simple cervical polyp and
was completely removed in the ofﬁce. Initial pathology returned as
endocervical adenocarcinoma with features of villoglandular adeno-
carcinoma. Post-procedure MRI was performed with no evidence of
cervical mass or metastasis. She was referred to a gynecologic oncol-
ogist who performed local excision with cold knife cone biopsy. Final
pathology revealed focal residual villoglandular adenocarcinoma in
the background of endocervical AIS, with negative margins (Fig. 1).
Subsequent management was discussed with the patient, and given
her undesired fertility and the understanding of the reported natural
history of villoglandular adenocarcinomadecisionwasmade to proceed
with robot-assisted laparoscopic extrafascial total hysterectomy with
ovarian conservation. Pathology showed residual adenocarcinoma in
situ with no invasive cancer. Follow-up is being conducted according
to SGO guidelines for cervical cancer (Salani et al., 2011). She remains
free of recurrence 18 month post-hysterectomy.
Stage IB1 cervical cancer is typically treated with radical hyster-
ectomy, radical trachelectomy or primary chemoradiation (National
Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology: Cervical Cancer, in Version 1.2014., 2014). This case seriesFig. 1. Low power ﬁeld demonstrating branched villous architecture. Neoplastic epithelium is p
endocervical stroma. Papillae are lined by endometrial and endocervical-type epithelium.demonstrates that IB1 villoglandular adenocarcinomawithout lympho-
vascular space invasion can be managed more conservatively, with
extrafascial hysterectomy or excision of the lesion with close follow-
up. Although much of the previously published literature on VGA
describes patients who were treated with radical surgery and/or radia-
tion therapy in concordance with standard treatment, many have also
reported conservative treatment with good outcomes such as ours.
One study described ﬁve patients with Stage I disease treated with
conization alone, all of whom were alive without recurrence at the
time of that publication, from 13 to 55 years after treatment (Jones
et al., 1993). Korach et al. described ﬁve cases of Stage I disease treated
with conservative therapy with no evidence of disease at the time of
publication: three cases of IA1, one treated with CKC and two treated
with total extrafascial hysterectomy, and two cases of IB1, both treated
with total hysterectomy (Korach et al., 2009).
Conservative or fertility-sparing therapymay not be beneﬁcial for all
patients depending on pathologic characteristics and stage including
lymph node (LN) metastasis. LN metastasis, although not a part of clin-
ical staging of cervical cancer, is an important prognostic factor. VGA
does not frequently metastasize to lymph nodes. Lataifeh et al. describe
12 patients with stage IB1, only one of whom was found to have pelvic
lymph nodemetastasis (Lataifeh et al., 2013). Utsugi et al. describe only
one of 13 patients with LNmets, whowas also Stage IIB. Of IB1 patients,
zero of 10 had LN mets (Utsugi et al., 2004). Lymphovascular space in-
vasion (LVSI) is another prognostic factor that may be less common in
VGA, as ﬁrst described by Young and Scully (Young and Scully, 1989;
Schorge et al., 1997). Utsugi et al. describe 13 cases, with 4 of the 13
patients having lymph capillary space invasion (Table 1).
Further follow-up of our patients andwomenwith the same diagno-
sis is needed to reveal long-term outcomes. Villoglandular adenocarci-
noma is a rare cervical cancer variant that deserves an individualized
approach tomanagement based on patient and physician interpretation
of risk, patient desires for future fertility and appropriate analysis of
subtle pathologic ﬁndings. Furthermore, accurate diagnosis is of utmostartially replacing the lining of some endocervical glands, however there is no invasion of
Table 1
Treatment and outcomes of stage 1 villoglandular adenocarcinoma in the literature.
Study # of cases Stage LVSI +LNs Treatment Outcome (at time of publication)
Lataifeh et al. 2013 11 IB1 – 1 RT + RH (6), RH (1), RH N RT (1), RTR (3), One pt with + LNs got RT, now NED, 10 NED
8 IB2 – 0 1 recurrence, 7 NED
Korach et al. 2009 3 IA1 – – CKC (2), TAH (1) NED
5 IB1 – – RH (3), TAH (2) 1 DOD in RH group, otherwise NED
Utsugi et al. 2004 10 IB1 2 0 RH (10) NED
Jones et al. 1993 24 IB1 0 0 RH (15), TAH + RT (4), CKC (5) NED
(CKC = cold knife conization, RH = radical hysterectomy (with lymph node dissection), RTR = radical trachelectomy, RT = radiation therapy, TAH/BSO = simple total abdominal
hysterectomy, DOD = died of disease).
36 S. Dilley et al. / Gynecologic Oncology Reports 12 (2015) 34–36importance if more conservative therapy is to be employed. Full biopsies
of the entire lesion are necessary for diagnosis (Korach et al., 2009).
Thoughtful pre-treatment counseling and close long-term follow-up is
essential in management of this rare tumor type.
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